ALLMedicine™ Neutropenia Center

Jan 15th, 2022 - Bloodstream infections (BSIs) cause morbidity and mortality in pediatric patients with leukemia. Antibiotic prophylaxis during periods of chemotherapy-induced neutropenia may reduce the incidence of BSIs. A levofloxacin prophylaxis guideline was i...

Jan 15th, 2022 - The additive or synergistic sustained antitumour effect of immune checkpoint inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. We investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy ...

Jan 14th, 2022 - The repeated use of doxorubicin is limited due to dose-limiting cardiac toxicity. Pegylated liposomal doxorubicin (PEG-LD, Duomeisu) has a reduced cardiac toxicity. This phase I study aimed to investigate the maximum tolerated doses (MTDs) and dos...

Jan 13th, 2022 - Neutropenia is a common and serious complication encountered during chemotherapy treatment of cancer patients. The incidence of neutropenia increases the risk of infection and can influence the chemotherapy treatment in terms of drug dosage and tr...

Jan 12th, 2022 - Neutropenia and antibiotic use put patients at risk for Clostridioides difficile infection (CDI) following allogenic hematopoietic cell transplant (alloHCT). CDI following alloHCT has been associated with acute graft versus host disease (aGVHD), a...

Nov 25th, 2020 - Patients with cancer are at higher risk of more severe COVID-19 infection and have more associated complications. The position paper describes the management of cancer patients, especially those receiving anticancer treatment, during the COVID-19 ...

Aug 19th, 2020 - The diagnosis of hypoglycemia and the use of diazoxide have risen in the last decade. Diazoxide is the only Food and Drug Agency-approved pharmacologic treatment for neonatal hypoglycemia caused by hyperinsulinism (HI). Recent publications have hi...

Nov 6th, 2018 - The range of pathology in adults that can produce abdominal pain is broad and necessitates an imaging approach to evaluate many different organ systems. Although localizing pain prompts directed imaging/management, clinical presentations may vary ...

Sep 5th, 2018 - To provide an updated joint ASCO/Infectious Diseases Society of America (IDSA) guideline on antimicrobial prophylaxis for adult patients with immunosuppression associated with cancer and its treatment. ASCO and IDSA convened an update Expert Panel...

Feb 21st, 2018 - Purpose To provide an updated joint ASCO/Infectious Diseases Society of American (IDSA) guideline on outpatient management of fever and neutropenia in patients with cancer. Methods ASCO and IDSA convened an Update Expert Panel and conducted a syst...

Jan 11th, 2022 - Lung cancer patients on a whole, and a significant percentage of NSCLC patients in particular, develop cancer cachexia. In fact, approximately 30-40% of all NSCLC patients will develop cachexia in their disease course, with the highest percentages...

Dec 29th, 2021 - Myelodysplastic syndromes (MDS) prevail in older age and are characterized by ineffective erythropoiesis and peripheral cytopenias. Supportive therapy is the main therapeutic option for most patients. Quality of Life (QoL) is mainly deteriorated b...

Dec 15th, 2021 - This is a prospective, observational cohort study to assess the frequency with which neutropenic patients with hematologic malignancies and hematopoietic cell transplant (HCT) recipients are colonized with fluoroquinolone-resistant Enterobacterale...

Dec 8th, 2021 - Blood stream infection (BSI) during febrile neutropenia (FN) is a lethal complication, while confirmed diagnosis via blood culture is usually with low sensitivity and time delay. The new technique of metagenome next generation sequencing (mNGS) ha...

Dec 7th, 2021 - Febrile neutropenia (FN) is a common complication of childhood cancer treatment and a leading cause of hospital admission and antibiotic exposure. Management typically involves broad-spectrum antibiotics until resolution of fever and absolute neut...

Jan 14th, 2022 - Anthony Mato, MD, discusses data from the following presentation: Updated results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor (BTKi) pirtobrutinib in patients with previously treated chronic lymphocytic leukemia/small lymphocy...

Jan 14th, 2022 - Zanubrutinib (Brukinsa) elicited a statistically significant improvement in progression-free survival (PFS) vs the combination of bendamustine and rituximab (Rituxan; BR) in patients with treatment-naïve chronic lymphocytic leukemia (CLL) and smal...

Jan 14th, 2022 - The combination of ibrutinib (Imbruvica) and rituximab (Rituxan) produced a high overall response rate (ORR) and durable survival in elderly patients with mantle cell lymphoma (MCL), according to data from a phase 2 ENRICH trial (NCT0180567) publi...

Jan 10th, 2022 - The novel antimetabolite aspacytarabine (BST-236) was found to produce a complete remission (CR) rate of 37% in adult patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive therapy, according to data from a phase 2b...

Jan 7th, 2022 - James K. McCloskey, MD, chief, Leukemia Division, John Theurer Cancer Center, Hackensack Meridian Health, discusses the utility of decitabine plus cedazuridine (Inqovi) in lower-risk myelodysplastic syndromes (MDS), based on data from the long-ter...